Sight Sciences Q3 revenue beats expectations, raises 2025 guidance

Sight Sciences

06/11/2025 22:03

Overview

Sight Sciences Q3 2025 revenue beats analyst expectations despite a 1% yr/yr decline

Company raises full-year 2025 revenue guidance to $76-78 mln, up from $72-76 mln

Operating expenses decreased 11% yr/yr in Q3 2025, including $2.8 mln in restructuring costs

Outlook

Sight Sciences raises 2025 revenue guidance to $76.0 mln to $78.0 mln

Company reduces 2025 adjusted operating expenses guidance to $90 mln to $92 mln

Company expects tariffs to increase Surgical Glaucoma costs by $1.0 mln to $1.5 mln in 2025

Result Drivers

SURGICAL GLAUCOMA GROWTH - Revenue growth driven by increased ordering accounts and higher average selling prices, despite coverage restrictions

DRY EYE REVENUE DECLINE - Significant decline due to focus on achieving reimbursed market access for TearCare procedures

OPERATING EXPENSE REDUCTION - Operating expenses decreased due to restructuring and cost management efforts

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$19.90 mln
$17.70 mln (6 Analysts)
Q3 Net Income
-$8.20 mln
Q3 Gross Margin
86.00%
Q3 Gross Profit
$17.20 mln
Q3 Operating Expenses
$25.10 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Sight Sciences Inc is $4.00, about 25.8% below its November 5 closing price of $5.03

Press Release: ID:nGNX6xypCY

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)